ALK-Abelló (CPSE:ALK B) Reports Strong ACARIZAX Data In China, Is The Stock Fully Priced?
Why this trial update matters for ALK-Abelló investors
ALK-Abelló (CPSE:ALK B) just reported positive phase 3 results for its ACARIZAX tablet in Chinese patients with house dust mite allergy, a key step toward potential approval in this large treatment market.
Investors have reacted to the ACARIZAX update in the context of an already strong run, with ALK-Abelló’s 30-day share price return of 23.02% and 90-day share price return of 15.46% feeding into a 1-year total shareholder return of 17.10% and a very large 3-year total shareholder return of about 21x. This indicates that momentum has been building rather than fading.
Spot other allergy and healthcare beneficiaries of this kind of clinical momentum by scanning our hand-picked 125 healthcare AI stocks alongside ALK-Abelló.Bulls see ACARIZAX momentum and China potential just starting to be reflected in ALK-Abelló’s price. Bears worry the recent surge already bakes in too much. Which side does the current valuation really lean toward?
Most Popular Narrative: 15% Undervalued
Against ALK-Abelló’s last close of DKK248, the most followed narrative points to a fair value of DKK291. This frames today’s level as meaningfully below that estimate while still grounded in detailed growth and margin assumptions.
The current valuation implies the share price does not fully reflect ALK-Abelló’s combination of double digit revenue growth, around 25% EBIT margins, tablet capacity investments and long term ambitions for at least 10% annual growth. This narrative presents that combination as an undervalued setup.
See why 22 investors see ALK-Abelló as 15% undervalued.
Result: Fair Value of DKK291 (UNDERVALUED)
Still, higher mandatory rebates in Germany and slower than hoped EURneffy uptake could weaken margins and challenge the current ALK-Abelló undervaluation story.
Find out about the key risks to this ALK-Abelló narrative.
Another View: ALK-Abelló through the earnings lens
On price versus fair value, ALK-Abelló screens as attractive at a 25.6% discount to intrinsic value. The picture looks very different when you look at the P/E. The stock trades at 40.6x earnings, almost double its 21.9x fair ratio, the 21.6x European pharmaceuticals average and the 20x peer group. Is the premium signalling quality, or is it simply stretching the margin for error?
To see how that earnings multiple stacks up against the underlying financials and what the market could move towards, See what the numbers say about this price — find out in our valuation breakdown..
Next Steps
With sentiment this divided around ALK-Abelló, it helps to move fast, dig through the underlying data and pressure test the story yourself. To see which potential upsides analysts currently flag and judge whether they justify the recent move, 3 key rewards
Looking for more investment ideas beyond ALK-Abelló?
If ACARIZAX has your attention, do not stop with ALK-Abelló. Put that curiosity to work and use a structured screener to surface fresh candidates.
- Target potential mispricing by scanning companies that combine solid fundamentals with attractive valuations through the 199 high quality undervalued stocks.
- Strengthen portfolio resilience by focusing on businesses that carry robust finances using the list of solid balance sheet and fundamentals (198 results).
- Hunt for under-the-radar opportunities by reviewing financially sound outsiders curated in the 612 high quality undiscovered gems.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com